Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.

Jing-Jing LiJiu-Hong WangYa DingvDan-Dan LiXi-Zhi WenJing-Jing ZhaoHang JiangXing LiuFu-Xue HuangXiao-Shi Zhang

Published in: Journal of cancer research and clinical oncology (2021)

Nab-paclitaxel combined with PD-1 antibody is a well-tolerated and effective regimen for Chinese patients with refractory melanoma.

Keyphrases